On this episode we’ll meet Thomas Fleming, Oxford-trained engineer, and co-founder and Chief Operating Officer of Arctoris a company that has developed a fully-autonomous drug discovery laboratory.

Founded in Oxford in 2016, Arctoris has staked their claim as the world’s first fully automated drug discovery platform. As the industry automates portions of the R&D pipeline, it will accelerate the development of novel medicines. Thomas and the team at Arctoris are working to accelerate that future.

This is the TomorrowScale podcast. Hosted by Justin Briggs.

Arctoris https://arctoris.com

Follow us on Twitter: http://twitter.com/tomorrowscale

Listen on Your Favorite Podcast App

The TomorrowScale Podcast was created to showcase scientists and entrepreneurs who are building science-based businesses, and to hear stories from the benches and in the trenches of research & development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thanks to our guests for sharing their time and knowledge with us. Thank you for listening. Please science responsibly.

  • On this episode, Ochre Bio co-founders join us to discuss turning discarded organs into a goldmine of biological insight with deep phenotypics that enables the company to pan for fine-grained expression of all the genes across millions of individual cells from different locations across an organ, and connect those signals to specific disease processes within [...]

    Continue reading
  • On this episode we’ll meet Dr. Daniel Levner, co-founder and […]

    Continue reading
  • On this episode we’ll take a walk, literally, with the […]

    Continue reading
  • On this episode, Ochre Bio co-founders join us to discuss turning discarded organs into a goldmine of biological insight with deep phenotypics that enables the company to pan for fine-grained expression of all the genes across millions of individual cells from different locations across an organ, and connect those signals to specific disease processes within [...]

    Continue reading
  • On this episode we’ll meet Dr. Daniel Levner, co-founder and […]

    Continue reading

Leave A Comment